Personalis (PSNL) Stock
Genomics services firm for cancer research partners. Here's the price, business snapshot, and what's worth knowing about Personalis in August 2026.
Personalis, Inc. (PSNL) is a clinical‑stage genomics company that provides advanced DNA sequencing, bioinformatics and immune profiling services used in oncology research and personalised cancer programmes. Its offerings include tumour–normal sequencing, neoantigen discovery, and adaptive immune receptor profiling, sold to biopharma partners and research institutions. Investors should know Personalis primarily earns revenue from service contracts and collaborations rather than marketed therapeutics, so growth depends on partner adoption and demand for precision oncology tools. As a small‑cap biotechnology firm (market cap ≈ $848.64M), PSNL can offer upside if its assays and proprietary analytics gain broader uptake, but it also carries typical sector risks: funding needs, competition, reimbursement and regulatory uncertainty. Financial performance can be variable and future profitability is not guaranteed. This is general educational information and not personalised investment advice; consider your risk tolerance and review the company’s filings or consult a financial adviser before investing.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Personalis Inc. stock, indicating potential for future price growth.
Financial Health
PERSONALIS INC shows moderate revenue and cash flow, but its profit margins are low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Precision Oncology Services
Demand for personalised cancer diagnostics and neoantigen discovery could drive revenue growth, though uptake and timing can vary and affect returns.
Proprietary Analytics Edge
Personalis’s bioinformatics and IP may differentiate its offering, but technological competition and execution risk remain important considerations.
Partner‑Led Growth
Revenue is often driven by collaborations with pharma and research centres, so progress depends on partner pipelines and commercial adoption.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
